Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET

Company Participants

David Connolly - Executive Director, IR and Corporate Communications
David Meeker - Chairman, President, and CEO
Jennifer Lee - Executive Vice President, Head of North America
Hunter Smith - Chief Financial Officer
Yann Mazabraud - Executive Vice President, Head of International

Conference Call Participants

Tazeen Ahmad - Bank of America
Corinne Jenkins - Goldman Sachs
Derek Archila - Wells Fargo
Phil Nadeau - TD Cowen
Whitney Ijem - Canaccord Genuity
Dae Gon Ha - Stifel
Joseph Stringer - Needham
Michael Higgins - Ladenburg Thalmann

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would like now to turn the conference over to David Connolly, Investor Relations and Corporate Communications. Please go ahead.

David Connolly

Thank you, Michelle. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section on the Investors page of our website, ir.rhythmtx.com.

This morning, we issued a press release that provides our Q4 year end 2023 financial results and a business update, which is available on our website. As listed on Slide 2 is our agenda. Here with me today in Boston are David Meeker, Chair, Chief Executive Officer and President of Rhythm Pharmaceuticals; Jennifer Li, Executive Vice President, Head of North America; Hunter Smith, our Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International is on the line joining us from Europe.